German HTA Body Calls For EU Legislative Reforms To Foster Better R&D Environment
Proposed revisions to the EU pharmaceutical legislation should do more to deliver a better data and research infrastructure to help propel European drug development and better clinical research, says IQWiG, Germany’s health technology assessment institute.
You may also be interested in...
New tendering rules in Belgium aim to improve competition between biosimilars and originators, for example by setting contract durations for tendering contracts and limiting the criteria for such contracts.
Important updates to good manufacturing practice guidelines are likely to mean medicine shortages, warns a German pharmaceutical industry group.
The IGBA has welcomed Mexican pharmaceutical industry association ANAFAM as an associate member.